Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Steatohepatitis Caused by Ingestible Alcohol Clear all
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

NCT04483947
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

NCT02855164
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor (LJN452), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
31
States / cities
Madison, Alabama • North Little Rock, Arkansas • Coronado, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Not applicable Interventional Results available

Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease

NCT03839082
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Interventions
Usual Care then FitBit, FitBit then Usual Care
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 11, 2026, 11:50 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815
View directory record Official record
Conditions
NON-ALCOHOLIC STEATOHEPATITIS
Interventions
DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Coronado, California • Montclair, California • Panorama City, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Not applicable Interventional Results available

Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

NCT04657523
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions
Investigational Liver Fat Quantification Software
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study in NASH to Assess IVA337

NCT03008070
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 11, 2026, 11:50 PM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879
View directory record Official record
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Not applicable Interventional

The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral

NCT07580482
View directory record Official record
Conditions
Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis
Interventions
Best Practice Alert, No Intervention
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

NCT04378010
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 1.5 mg, EDP-305 2 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
68
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 11, 2026, 11:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03812029
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Vonafexor, Placebo
Drug · Other
Lead sponsor
Enyo Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Lakewood Rch, Florida • Ocoee, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT00845845
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Interventions
Omega-3-acid ethyl esters (Lovaza), Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 11, 2026, 11:50 PM EDT
Completed No phase listed Observational

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2

NCT01030484
View directory record Official record
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
8
States / cities
La Jolla, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 1 Interventional Results available

AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis

NCT04897594
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-201, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 11, 2026, 11:50 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 11, 2026, 11:50 PM EDT
Completed No phase listed Observational

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05357352
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Interventions
NAFLD/NASH
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 11, 2026, 11:50 PM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 11, 2026, 11:50 PM EDT
Completed No phase listed Observational

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

NCT04454463
View directory record Official record
Conditions
Liver Diseases
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
2 Years and older
Enrollment
1,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 11, 2026, 11:50 PM EDT